Federal Preemption Defense Against Product Liability Weakened In House Bill
Executive Summary
A one-sentence provision tucked into draft House legislation renewing FDA's drug user fee program seeks to weaken manufacturers' ability to use FDA approval as a defense in state product liability lawsuits
You may also be interested in...
FDA’s Labeling Rule Should Be Tweaked, Firms Say; Dems Want It Squashed
FDA appears to have a relatively smooth task ahead of itself as it works to finalize its proposed rule delineating when firms can change product labels without prior agency approval since the comments supporting the proposal contain few suggested changes
FDA’s Labeling Rule Should Be Tweaked, Firms Say; Dems Want It Squashed
FDA appears to have a relatively smooth task ahead of itself as it works to finalize its proposed rule delineating when firms can change product labels without prior agency approval since the comments supporting the proposal contain few suggested changes
Preemption Remains Conference Issue In FDA Bill As Both Sides Declare Victory
The impact of FDA reform legislation on product liability lawsuits could depend in large part on how the House and Senate resolve subtle differences in phrasing between the two chambers' bills